Patents Assigned to Merck
  • New stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
    Publication number: 20180134711
    Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 17, 2018
    Applicant: MERCK & CIE
    Inventors: Rudolf MOSER, Viola GROEHN, Thomas EGGER, Thomas AMMANN
  • LIQUID-CRYSTAL MEDIUM
    Publication number: 20180134959
    Abstract: The present invention relates to a liquid crystal (LC) medium comprising a polymerisable compound, to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in an LC display of the polymer sustained alignment (PSA) type, and to an LC display, especially a PSA display, comprising it.
    Type: Application
    Filed: April 29, 2016
    Publication date: May 17, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Eun-Kyu LEE, Jin-Soon PARK, Hyun-Jin YOON, Min-OK JIN, Yong-Kuk YUN
  • 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
    Publication number: 20180134712
    Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.
    Type: Application
    Filed: May 24, 2016
    Publication date: May 17, 2018
    Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.
    Inventors: Dong-Ming Shen, Michael P. Dwyer, Christopher J. Sinz, Deping Wang, Shawn J. Stachel, Daniel V. Paone, Ashley Forster, Richard Berger, Yilli Chen, Yimin Qian, Shimin Xu, Chunmel Hu, William D. Shipe, Jianmin Fu, Zhigang Guo, HAITANG LI, Yingjian Bo
  • TARGETING AMINOACID LIPIDS
    Publication number: 20180133334
    Abstract: The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Optionally one or more further bioactive agents may be encapsulated or embedded within or attached to or adsorbed onto the carrier system. The present invention is further directed to methods of their preparation and their uses in medical applications, such as targeted delivery of bioactive agents to specific tissues or cells and antigen display systems for the study, diagnosis, and treatment of traits, diseases and conditions that respond to said bioactive agents.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Applicant: Merck Patent GmbH
    Inventors: Michael PLATSCHER, Raymond BEHRENDT, Viola GROEHN, Simone HOERTNER, Marco PASSAFARO, Finn BAUER
  • Factor IXa inhibitors
    Patent number: 9969724
    Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: May 15, 2018
    Assignees: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Isao Sakurada, Tomokazu Hirabayashi, Yoshitaka Maeda, Hiroshi Nagasue, Takashi Mizuno, Jiayi Xu, Ting Zhang, Cameron Smith, Dann Parker
  • Formulations containing conductive polymers and use thereof in organic electronic devices
    Patent number: 9972782
    Abstract: The invention relates to formulations containing doped conductive polymers, which due to outstanding hole injection characteristics and high conductivity are very suitable for use in organic electronic devices, preferably in organic electroluminescent devices, in particular in the buffer layers thereof. Thus the invention further relates to the use of the formulations according to the invention in organic electronic devices, preferably in electroluminescent devices, in particular in the buffer layers thereof.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: May 15, 2018
    Assignee: Merck Patent GmbH
    Inventors: Heinrich Becker, Susanne Heun
  • Heteroaryl compounds as IRAK inhibitors and uses thereof
    Patent number: 9969710
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 15, 2018
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Ruoxi Lan, Austin Chen, Ryan C. Clark
  • Inhibitors of HIF prolyl hydroxylase
    Patent number: 9969752
    Abstract: The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiaqiang Cai, Alejandro Crespo, Xiaoxing Du, Byron Gabriel Dubois, Deodialsingh Guiadeen, Shankaran Kothandaraman, Ping Liu, Rongqiang Liu, Weiguo Quan, Christopher Sinz, Liping Wang
  • Methods of modulating cytokine activity; related reagents
    Patent number: 9970944
    Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jochen Schmitz, Martin Oft, Robert A. Kastelein, J. Fernando Bazan
  • Pharmaceutical salts of an orexin receptor antagonist
    Patent number: 9969725
    Abstract: The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is further directed to pharmaceutical compositions comprising pharmaceutically acceptable salts of suvorexant.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael McNevin, Sachin Lohani
  • Inhibitors of IRAK4 activity
    Patent number: 9969749
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian M. Andresen, Jason D. Brubaker, Matthew L. Childers, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Solomon D. Kattar, Charles A. Lesburg, Jongwon Lim, John K. F. MacLean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Luis Torres
  • DEVICE FOR SUBSTANCE SEPARATION
    Publication number: 20180126298
    Abstract: The invention relates to a device for substance separation with monolithic sorbents which can be produced by means of 3-D printing. They comprise pressure- and solvent-stable thermoplastics.
    Type: Application
    Filed: May 2, 2016
    Publication date: May 10, 2018
    Applicant: Merck Patent GmbH
    Inventors: Karin CABRERA, Klaus KREHER, Gisela JUNG
  • INDAZOLE AND AZAINDAZOLE BTK INHIBITORS
    Publication number: 20180127411
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Application
    Filed: April 4, 2016
    Publication date: May 10, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Tony SIU, Michael D. ALTMAN, Brian M. ANDRESEN, Jian LIU, Joseph KOZLOWSKI, Sobhana Babu BOGA, Younong YU, Rajan ANAND, Jiaqiang CAI, Dahai WANG, Shilan LIU
  • METHODS OF MODULATING CYTOKINE ACTIVITY; RELATED REAGENTS
    Publication number: 20180128837
    Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 10, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jochen Schmitz, Martin Oft, Robert A. Kastelein, J. Fernando Bazan
  • INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS
    Publication number: 20180127417
    Abstract: The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are CGRP receptor antagonists useful for the treatment of migraine.
    Type: Application
    Filed: December 19, 2017
    Publication date: May 10, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Frank Chen, Carmela Molinaro, W. Peter Wuelfing, Nobuyoshi Yasuda, Jianguo Yin, Yong-Li Zhong, Joseph Lynch
  • Antibody neutralizing human respiratory syncytial virus
    Patent number: 9963500
    Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 8, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kalpit A. Vora, Kara S. Cox, Aimin Tang, Zhifeng Chen, Daniel DiStefano, Lan Zhang, Hua-Poo Su
  • Liquid crystal medium
    Patent number: 9963637
    Abstract: The present invention relates to a liquid crystalline medium comprising a polymerizable compound, to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in liquid crystalline displays, especially in a liquid crystalline display of the polymer sustained alignment (PSA) type, and to a liquid crystalline display, especially a PSA display, comprising it.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: May 8, 2018
    Assignee: Merck Patent GmbH
    Inventors: Eun-Kyu Lee, Hyun-Jin Yoon, Ji-Won Jeong, Hye-Ryung Park, Seung-Jai Kim, Yong-Jun Ji, Min-Ok Jin, Yong-Kuk Yun
  • LIQUID-CRYSTALLINE MEDIUM
    Publication number: 20180119010
    Abstract: The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, in which R1, R1*, rings A and B, Z1, L1, L2, a and b have the meanings indicated in Claim 1, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, IPS or PS-IPS effect.
    Type: Application
    Filed: December 29, 2017
    Publication date: May 3, 2018
    Applicant: Merck Patent GmbH
    Inventors: Melanie KLASEN-MEMMER, Achim GOETZ, Georg BERNATZ
  • WAVELENGTH CONVERSION POLYMER FILM
    Publication number: 20180122974
    Abstract: The invention relates to a polymer film comprising an inorganic fluorescent compound and an organic fluorescent compound. The invention further relates methods for preparing such a film, and to its use as wavelength conversion film in a solar cell.
    Type: Application
    Filed: December 18, 2017
    Publication date: May 3, 2018
    Applicant: Merck Patent GmbH
    Inventors: Hiroshi OKURA, Takeo WAKIMOTO, Katsuyuki MATSUI, Noriyuki MATSUDA, Masayoshi SUZUKI, Tadashi KISHIMOTO
  • PYRIMIDINE DERIVATIVES
    Publication number: 20180118721
    Abstract: Compounds of Formula I or II in which R1, X1 and X2 have the meanings indicated in claim 1, are MTH1 inhibitors and can be employed, inter alia, in the treatment of cancer.
    Type: Application
    Filed: February 12, 2016
    Publication date: May 3, 2018
    Applicant: Merck Patent GmbH
    Inventors: Timo HEINRICH, Ulrich PEHL